Please login to the form below

Not currently logged in
Email:
Password:

NICE guidance on cervical cancer

NICE has recommended topotecan in combination with cisplatin as a treatment option for women with recurrent or stage IVB cervical cancer

The UK's National Institute for Health and Clinical Excellence (NICE) has published final guidance recommending the use of topotecan in combination with cisplatin as a treatment option for women with recurrent or stage IVB cervical cancer who have not previously received cisplatin.

Women who have previously received cisplatin and are currently being treated with topotecan in combination with cisplatin for recurrent and stage IVB cervical cancer should have the option to continue their therapy until they and their clinicians consider it appropriate to stop.

Topotecan prevents DNA replication in cancer cells by inhibiting the enzyme topoisomerase I, which helps to separate and repair the DNA in cells when they divide.

Dr Carole Longson, the Health Technology Evaluation Centre director, said: "The independent Appraisal Committee considered all available evidence on the effectiveness of topotecan as a treatment for women with cervical cancer. They also heard evidence from patients who highlighted the importance of having a number of treatment options because one may be more suitable than others for the individual patient. The committee concluded that - for women with recurrent cervical cancer and those with stage IVB cervical cancer, where cancerous cells have spread to distant organs, such as the lungs, and who have not previously received cisplatin - the cost of topotecan in relation to how well it works is an effective use of NHS resources.

"Cervical cancer affects approximately 2,800 women in the UK each year. Currently a range of therapies is used to treat the cancer with no single best practice treatment. Today's guidance means that those patients who meet the above criteria will have a further treatment option."

29th October 2009

From: Healthcare

Share

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
An agency called Owen

We’re a Healthcare Communications Agency specialising in Multi-channel Marketing to make you Digitally Fitter, Stronger & Faster....

Latest intelligence

The social dilemma: is it time for pharma to join the party?
Chris Ross explores why social media still isn’t trending for pharma, and how it can join in the fun...
MIT reveals new pill to deliver insulin
A new MIT research project, sponsored by Novo Nordisk, is aiming to deliver insulin orally with a pill that releases medicine in the stomach lining. Dina Patel interviews the team...
Fearless Girl cover
25 Women Leaders in UK Healthcare
Women trailblazers helping to shape the future of healthcare (Part 1)...

Infographics